Status:
UNKNOWN
Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Positron-Emission Tomography
Eligibility:
All Genders
18-75 years
Brief Summary
To explore the value of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in early diagnosis of treatment-related cardiotoxicity (TACT) of lymphoma using visual method and semi-quantitative method.
Detailed Description
First of all, the cardiac 18F-FDG uptake in patients with lymphoma will be observed by visual method: according to the uptake site, it will be divided into left ventricular uptake and biventricular up...
Eligibility Criteria
Inclusion
- No previous history of heart disease.
- normal echocardiography, ECG and laboratory tests (creatine kinase, myoglobin, troponin, brain natriuretic peptide) before treatment.
- 18F-FDG PET/CT examination before and after treatment
- \-
Exclusion
- receiving radiotherapy and chemotherapy at the same time. 2.previous chest radiotherapy. 3. with severe hepatic or renal dysfunction.
- \-
Key Trial Info
Start Date :
June 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05411250
Start Date
June 1 2022
End Date
July 31 2023
Last Update
June 9 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.